Neuphoria Therapeutics Reports 92.5% Revenue Decline, Restructures Operations Amid Merger Plans

Neuphoria Therapeutics Inc., a clinical-stage biotechnology company, reported a significant decline in revenue for the fiscal year ending June 30, 2026, with total revenue of $1.2 million, down 92.5% from $15.6 million in the previous year. This decrease was primarily attributed to the absence of a substantial licensing milestone payment from Merck, which had contributed $15 million in the prior fiscal year. The company’s accumulated deficit reached $191.8 million, and it ended the fiscal year with cash and cash equivalents of $19.9 million. Neuphoria has not yet generated any product revenue and anticipates continued operating losses as it navigates the complexities of drug development.

In terms of operational changes, Neuphoria has undergone a significant restructuring, terminating all but one full-time employee and pausing major research and development activities, including the clinical development of its lead product candidate, BNC210, for social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD). The company is currently focused on completing a proposed merger with Scancell Holdings plc, which is expected to close in late 2026, subject to various regulatory and shareholder approvals. The merger is seen as a strategic move to preserve cash and maintain public company obligations while managing intellectual property and economic interests in partnered programs.

The company’s research and development expenses decreased by 60.6% to $3.5 million, reflecting the halt in internal R&D activities. General and administrative expenses also saw a slight reduction of 4.3% to $7.4 million, primarily due to decreased headcount-related costs. However, Neuphoria recorded a goodwill impairment charge of approximately $5.4 million, attributed to the suspension of Merck's Alzheimer’s trial, which impacted the expected future cash flows associated with the company’s assets.

Neuphoria's future outlook remains uncertain, hinging on the successful completion of the merger with Scancell and the potential resumption of clinical trials for BNC210. The company has indicated that its existing cash reserves are expected to sustain operations beyond the second quarter of fiscal year 2028, but it will require additional financing to support ongoing and future development activities. The company’s ability to generate revenue will depend heavily on the successful development and commercialization of its product candidates, which are currently in various stages of clinical development.